JPMorgan analyst Eric Joseph raised the firm’s price target on Akero Therapeutics to $62 from $49 and keeps an Overweight rating on the shares. With topline data from the Phase 2b SYMMETRY study slated to readout out in October, the firm updated the company’s model with a paired scenario analysis into the event. The analyst remains confident in EFX’s meaningful fibrosis-lowering profile extending into the F4 population, and says current share levels are “under-reflecting” the asset’s commercial potential across the F3/F4 setting on a risk-adjusted basis.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AKRO:
- Akero Therapeutics to Present at Upcoming Healthcare Conferences in September
- 89bio initiated with a Buy at UBS
- Akero Therapeutics initiated with a Buy at UBS
- Akero Therapeutics to report Phase 2b SYMMETRY results in October
- Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023